Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 88.16% | 87.88% | 52.28% | 53.46% | -55.54% |
| Total Depreciation and Amortization | -2.51% | -0.42% | -5.47% | -8.02% | -5.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.02% | -93.88% | 174.63% | 167.95% | -19.26% |
| Change in Net Operating Assets | -21.97% | -24.80% | 26.69% | 28.50% | -115.22% |
| Cash from Operations | 83.89% | 83.52% | 46.34% | 47.66% | -184.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | 2.65% | 1.30% | 3.80% | -0.66% |
| Cash from Investing | 0.00% | 2.65% | 1.30% | 3.80% | -0.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.84% | -12.84% | -5.81% | -5.81% | 8.87% |
| Issuance of Common Stock | -46.87% | -46.87% | -100.00% | -100.00% | -54.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 53.18% | 53.18% | -- | -- | 53.17% |
| Cash from Financing | -46.59% | -45.34% | -152.47% | -151.18% | -54.98% |
| Foreign Exchange rate Adjustments | 112.22% | 112.75% | -78.86% | -74.42% | 68.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.54% | 131.25% | 43.76% | 45.15% | -151.02% |